Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
report entities : Nrx pharmaceuticals inc save search
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 895.97%
H: 14.34%
C: 11.7%
business year update pharmaceuticals financial results
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
Published: 2024-03-28 (Crawled : 12:00) - prnewswire.com
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: -9.43%
H: 12.5%
C: -1.69%
year pharmaceuticals financial results
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Published: 2024-03-26 (Crawled : 20:00) - prnewswire.com
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 2.58%
H: 3.89%
C: 0.13%
report year pharmaceuticals financial results
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
Published: 2024-03-21 (Crawled : 20:00) - prnewswire.com
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 2.95%
H: 15.38%
C: 7.69%
report year update pharmaceuticals financial results
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
Published: 2024-02-09 (Crawled : 13:30) - prnewswire.com
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 4.31%
H: 9.48%
C: 5.79%
report financial
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-13 (Crawled : 00:00) - prnewswire.com
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 4.32%
H: 0.0%
C: 0.0%
business update pharmaceuticals financial results
NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023
Published: 2023-08-07 (Crawled : 12:00) - biospace.com/
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 8.66%
H: 0.0%
C: -13.92%
report pharmaceuticals financial results
NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Published: 2023-05-16 (Crawled : 12:00) - biospace.com/
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 6.25%
H: 0.0%
C: -12.72%
business update pharmaceuticals financial results
NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
Published: 2023-03-30 (Crawled : 22:00) - biospace.com/
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 0.28%
H: 2.39%
C: -1.99%
business year update pharmaceuticals financial results
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
Published: 2023-03-17 (Crawled : 12:20) - biospace.com/
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 1.85%
H: 2.86%
C: 1.37%
report year pharmaceuticals financial results
NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality
Published: 2023-02-13 (Crawled : 16:00) - biospace.com/
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 0.0%
H: 4.46%
C: 1.79%
nrx-101 pharmaceuticals drug meeting food depression
NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
Published: 2023-02-02 (Crawled : 12:00) - prnewswire.com
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: -0.85%
H: 6.84%
C: 6.84%
nrx-101 pharmaceuticals trial depression
NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-14 (Crawled : 12:00) - prnewswire.com
RLFTF | $1.45 1.3K
|
n/a
|
| O: 1.45%
H: 0.0%
C: -3.43%
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -9.99%
pharmaceuticals financial update results
NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022
Published: 2022-11-10 (Crawled : 12:00) - prnewswire.com
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: -0.01%
H: 2.09%
C: 1.43%
pharmaceuticals report results
NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise
Published: 2022-08-15 (Crawled : 12:00) - biospace.com/
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 0.04%
H: 0.25%
C: -6.33%
update results
NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022
Published: 2022-08-10 (Crawled : 12:00) - prnewswire.com
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 2.73%
H: 1.04%
C: 0.91%
report results
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
Published: 2022-07-04 (Crawled : 10:00) - biospace.com/
RLFTF | $1.45 1.3K
|
n/a
| Email alert
Add to watchlist
RLFTY | $1.4006 733.33% 100
|
n/a
| Email alert
Add to watchlist
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
| Email alert
Add to watchlist
covid-19 fda risk collaboration aviptadil authorization emergency use authorization
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
Published: 2022-06-13 (Crawled : 07:00) - biospace.com/
RLFTF | $1.45 1.3K
|
n/a
|
| O: -10.92%
H: 14.19%
C: -0.32%
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: -8.21%
H: 7.26%
C: -3.08%
designation collaboration aviptadil
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
RLFTF | $1.45 1.3K
|
n/a
|
| O: -9.48%
H: 4.19%
C: -39.05%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: -40.54%
H: 20.91%
C: -15.45%
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: -38.37%
H: 1.11%
C: -32.16%
covid-19 collaboration aviptadil health
NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Published: 2022-05-16 (Crawled : 12:00) - biospace.com/
NRXP 5 d | $3.1 1.64% 51K
|
Manufacturing
|
| O: 12.45%
H: 5.0%
C: -2.86%
results
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.